WSJ News Exclusive | How Novartis’s CEO Learned From His …
WEBSep 3, 2023 · After some deals and drug launches disappointed, Vas Narasimhan heard from investors—and hired an outspoken Wall Street analyst to manage strategy.
'It was never my plan to be the boss of a huge company' - BBC
WEBWhen Vas Narasimhan was told he was being considered for the top job at Swiss drugs giant Novartis, he thought there had been a mistake.
Vasant Narasimhan | Novartis
WEBJan 31, 2024 · Vasant (Vas) Narasimhan, M.D. Since becoming CEO of Novartis in 2018, Vas has led a strategic and cultural transformation to build a fully focused medicines company—one that delivers high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches.
Vas Narasimhan: the American trying to reshape Novartis - Financial Times
WEBFeb 4, 2022 · Novartis has since announced a $15bn share buyback plan, helping lift a stock that has only gained 10 per cent since Narasimhan took over and lagged the advance in the Stoxx Europe 600 Healthcare...
Novartis CEO on Acquisitions, AI, Weight-Loss Drugs
WEBFeb 16, 2024 · Novartis CEO Vas Narasimhan talks about acquisitions, AI and the future of weight-loss drugs. He speaks on "The David Rubenstein Show: Peer-to-Peer Conversations." This interview was recorded...
Novartis unveils new focused strategy, underpinned by eight …
WEBSep 22, 2022 · “Novartis is transforming into a ‘pure-play’ Innovative Medicines company. Our strategy is focused on five core attractive therapeutic areas, key technology platforms, and the US market, with the aim to increase value per new molecular entity from our deep pipeline”, said Vas Narasimhan, CEO of Novartis.
Watch CNBC’s full interview with Novartis CEO Vas Narasimhan
WEBOct 3, 2023 · Novartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss the company's new spin-off Sandoz, what a pure-play core pharmaceutical company means, and the idea of M&A to boost the...
Novartis announces new organizational structure to accelerate …
WEBApr 4, 2022 · During his 20-year tenure at Novartis, he held several global leadership roles including as development head for the company’s Neuroscience franchise and Global Head of Medical Affairs for the Pharmaceuticals business unit. Dr. Aradhye will report to Vas Narasimhan and join the ECN.
Novartis CEO Vas Narasimhan Sees Remote-Work Hybrid Persisting After ...
WEBApr 27, 2021 · Novartis AG, the Swiss pharma giant, is rethinking its use of office space as a hybrid of at-home and in-office work extends beyond the pandemic. “We think this is the future,” Chief Executive ...
Novartis Is Working on the Next Wave of Obesity Drugs, CEO Says
WEBFeb 16, 2024 · Novartis AG Chief Executive Officer Vas Narasimhan says the drugmaker aims to compete in the growing obesity market by designing next-generation treatments. “We think there’s opportunity to improve,” Narasimhan said in an interview with David Rubenstein for Bloomberg TV.